Clinical Guides
Hypercalcaemia
A clinically focused, India-facing guide to confirming hypercalcaemia, separating urgent calcium crisis from chronic causes, and selecting monitored cause-directed treatment.
MedNext Academy | 12 min read
Hypercalcaemia
A clinically focused, India-facing guide to confirming hypercalcaemia, separating urgent calcium crisis from chronic causes, and selecting monitored cause-directed treatment.
Summary
Hypercalcaemia is an elevated circulating calcium concentration, preferably interpreted as albumin-adjusted calcium or with an appropriate ionised-calcium measurement when the clinical setting requires it. It is a biochemical abnormality, not a diagnosis. The two commonest causes are primary hyperparathyroidism and malignancy, but medicines, vitamin D-related disorders, granulomatous disease, renal and endocrine disorders, immobilisation and familial hypocalciuric hypercalcaemia are important alternatives. The same numerical calcium value can be tolerated differently depending on rapidity of rise, volume status, kidney function, age and cause.
Symptoms range from thirst, polyuria, constipation, nausea, weakness and cognitive change to acute kidney injury, shortened QT interval, dysrhythmia, coma and pancreatitis. Society for Endocrinology emergency guidance describes calcium below 3.0 mmol/L as often asymptomatic, 3.0-3.5 mmol/L as potentially symptomatic and usually needing prompt treatment, and above 3.5 mmol/L as requiring urgent correction because of dysrhythmia and coma risk. These are guidance categories, not permission to manage a symptomatic patient at home.
The first tasks are to confirm the result, assess severity, obtain ECG and renal function, restore volume safely and determine whether parathyroid hormone is inappropriately high or appropriately suppressed. Treatment differs sharply between primary hyperparathyroidism and hypercalcaemia of malignancy. This guide does not give a universal infusion or drug dose; local acute-medicine, oncology, renal and endocrine supervision is required.
How Common Is It?
The frequency of hypercalcaemia depends on setting and definition. Asymptomatic primary hyperparathyroidism is often detected through chemistry testing, whereas severe presentations in hospital can be driven by dehydration, malignancy or medication. Hypercalcaemia of malignancy is a serious metabolic complication in advanced cancer, but its observed frequency changes with tumour type, stage, measurement practice and use of bone-targeted therapies. A prevalence figure from a tertiary oncology unit cannot describe primary-care testing or an Indian population.
The Society for Endocrinology states that primary hyperparathyroidism and malignancy account for about 90% of cases in its acute framework. That is a useful diagnostic heuristic, not a substitute for a medication review, PTH measurement and clinical context. Incidental mild hypercalcaemia may be chronic and clinically quiet, while a rapidly rising value with only moderate biochemical elevation can produce severe dehydration or delirium. Incidence statistics do not predict risk in the individual patient.
India does not have one contemporary, representative registry for all laboratory-confirmed hypercalcaemia, primary hyperparathyroidism or cancer-associated hypercalcaemia. Case mix varies with access to automated chemistry, vitamin D supplements, endocrine surgery, cancer services and renal replacement therapy. Report local data with population, assay, albumin correction, year and referral setting. For practice, the important question is whether the result is real, changing, symptomatic or associated with malignancy, renal dysfunction, stones or fractures—not whether it resembles an imported prevalence estimate.
Risk Factors
Primary hyperparathyroidism should be considered in persistent raised calcium with an inappropriately non-suppressed PTH, renal stones, osteoporosis, fragility fracture, thirst, polyuria or constipation. A history of neck irradiation, lithium use, renal impairment or familial endocrine disease can alter probability. Familial hypocalciuric hypercalcaemia is usually mild and may be mistaken for primary hyperparathyroidism; family history and urine calcium assessment matter before unnecessary surgery.
Malignancy risk is raised by known cancer, weight loss, bone pain, anaemia, renal impairment or a suppressed PTH, but a normal examination does not exclude cancer. Mechanisms include humoral factors, osteolytic lesions and calcitriol-mediated disease such as lymphoma. Immobilisation, excess calcium or vitamin D intake, granulomatous disease, thyrotoxicosis, adrenal insufficiency, milk-alkali syndrome and medicines including thiazides and lithium are recognised causes. Review non-prescription calcium, vitamin A or D, bodybuilding products and traditional medicines as carefully as prescriptions.
Dehydration can magnify hypercalcaemia and its renal consequences. Older age, frailty, reduced thirst, diuretics, vomiting and diarrhoea increase this risk. Chronic kidney disease complicates interpretation and limits fluid and antiresorptive options. Pregnancy, heart failure and severe renal impairment change the acceptable rate and volume of rehydration. Risk assessment must distinguish a causal medicine from a coincidental medicine and must never stop lithium, a thiazide or prescribed supplements abruptly without discussing the indication and a safe substitute.
Diagnosis
History
Ask about thirst, polyuria, nocturia, constipation, nausea, vomiting, anorexia, abdominal pain, proximal weakness, mood change, confusion, falls, bone pain, renal colic, fracture, weight loss and cancer symptoms. Establish onset and previous calcium results, fluid intake, mobility, renal disease, pregnancy, cancer history and family history of hypercalcaemia, stones or endocrine tumours. Reconcile every medicine and supplement, including thiazides, lithium, calcium, vitamin D, antacids and herbal preparations.
Examination
Assess dehydration, blood pressure, pulse, postural symptoms, mental state, proximal power, abdominal tenderness, bone tenderness, volume status and evidence of malignancy. Obtain an ECG for shortened QT or other conduction abnormality. Look for a neck mass only as part of a broader examination; a normal neck does not exclude parathyroid disease. Confusion, reduced consciousness, dysrhythmia, hypotension or oliguria changes the setting from outpatient investigation to emergency management.
Investigations
Repeat albumin-adjusted calcium when appropriate, assess creatinine or eGFR, urea, electrolytes, phosphate, magnesium and PTH with concurrent calcium. Current guidelines recommends PTH when albumin-adjusted calcium is at least 2.6 mmol/L on two occasions, or at least 2.5 mmol/L twice with suspected primary hyperparathyroidism. High calcium with non-suppressed PTH suggests primary or tertiary hyperparathyroidism; suppressed PTH directs a malignancy and non-PTH work-up. Vitamin D, urinary calcium, serum protein studies, PTH-related peptide, calcitriol, imaging and malignancy testing are targeted, not indiscriminate.
Differential Diagnosis
Start with PTH. Inappropriately normal or raised PTH with hypercalcaemia supports primary hyperparathyroidism, tertiary hyperparathyroidism or lithium-associated disease. Familial hypocalciuric hypercalcaemia is a key mimic because it is usually mild and does not benefit from parathyroidectomy; Current guidelines recommends measuring urine calcium excretion by a 24-hour collection, calcium:creatinine ratio or clearance ratio to distinguish it from primary hyperparathyroidism.
Suppressed PTH suggests malignancy or another non-PTH cause. Consider PTH-related peptide-mediated malignancy, osteolytic metastases or myeloma, calcitriol-mediated lymphoma or granulomatous disease, vitamin D intoxication, milk-alkali syndrome, thyrotoxicosis, adrenal insufficiency, immobilisation and medication effect. Serum and urine protein studies, chest imaging, skeletal imaging and endocrine tests should answer a specific question. A high calcium concentration does not by itself establish metastatic cancer.
Pseudo-hypercalcaemia can occur when total calcium is distorted by albumin or protein abnormalities. Acid-base status changes ionised calcium and acute illness may make formula-based correction less reliable. Kidney failure, dehydration and medications can coexist with either primary hyperparathyroidism or malignancy. Hypercalcaemia with abdominal pain should not be assumed to explain all pain: pancreatitis, obstruction, renal colic, perforation and malignancy need their own assessment. Clinical urgency is based on symptoms, ECG, renal function, rise and cause as well as the reported calcium.
Management
Treat severe or symptomatic hypercalcaemia as an acute medical problem while seeking the cause. Assess airway, circulation, mental state, ECG, renal function, urine output and volume status. Society for Endocrinology emergency guidance recommends rehydration with intravenous 0.9% saline, with monitoring for overload in older patients and people with renal impairment or heart failure. Loop diuretics are not a routine calcium-lowering therapy; they are considered only for fluid overload. Dialysis may be needed when severe renal failure prevents safe management.
After rehydration, cause and severity guide antiresorptive or endocrine therapy. For hypercalcaemia of malignancy, the Endocrine Society recommends an intravenous bisphosphonate or denosumab; severe disease above 14 mg/dL (3.5 mmol/L) may need calcitonin combined with one of these initially, with calcitonin limited to 48-72 hours because of tachyphylaxis. Calcitriol-mediated malignancy is treated first with glucocorticoids in that guidance. Denosumab, bisphosphonate and calcitonin decisions require renal, dental, pregnancy and malignancy review.
Primary hyperparathyroidism requires definitive assessment for surgery, renal and skeletal involvement. current guidelines refers people with symptoms, end-organ disease or albumin-adjusted calcium at least 2.85 mmol/L to an experienced parathyroid surgeon. Cinacalcet is an option in selected non-surgical cases but does not replace cause-directed surgery. Recheck calcium, renal function and symptoms after every intervention, identify reversible medication or supplement causes, and coordinate oncology, endocrine, renal and acute medicine care.
Prescribing Information
Intravenous saline is a treatment, not a benign default. Prescribe volume and rate after examining perfusion, lung signs, renal function and cardiac history; monitor input, output, weight, electrolytes and pulmonary oedema. In heart failure, advanced kidney disease or frailty, aggressive fluid replacement can harm. Loop diuretics do not routinely lower calcium and can worsen dehydration, so use only when overload develops under supervision.
Intravenous bisphosphonates can worsen renal function and may cause hypocalcaemia, especially with vitamin D deficiency or suppressed PTH. Society guidance advises slower administration and dose reduction consideration in renal impairment. Check renal function, calcium, phosphate, magnesium and dental risk, and avoid treating an unconfirmed laboratory result. Denosumab can be useful when bisphosphonates are unsuitable but also carries profound hypocalcaemia risk, particularly in severe kidney disease; arrange calcium monitoring and specialist oversight. Calcitonin has rapid but short-lived benefit and should not continue beyond 48-72 hours in the Endocrine Society malignancy recommendation.
Glucocorticoids are not universal hypercalcaemia drugs; they are relevant to calcitriol-mediated causes such as lymphoma or granulomatous disease. Cinacalcet has a cause-specific role in selected primary hyperparathyroidism or parathyroid carcinoma and may cause nausea and hypocalcaemia. In India, confirm CDSCO labelling, local supply, infusion facilities, renal protocols and cost. This guide intentionally gives no dose regimen. Stop or alter thiazides, lithium, calcium or vitamin D only with the clinician managing the underlying condition.
When to Refer
Send a patient urgently to hospital for calcium above 3.5 mmol/L, marked symptoms, dehydration not correctable orally, altered mental state, arrhythmia, ECG change, acute kidney injury, oliguria, severe vomiting or suspected malignancy-related crisis. The numerical threshold is an aid: a symptomatic or rapidly rising calcium below it still needs urgent assessment, and a chronic mild elevation may be safely investigated only when the patient is stable and reliable follow-up exists.
Refer probable primary hyperparathyroidism to endocrinology and an experienced parathyroid surgeon for symptoms, stones, osteoporosis, fragility fracture, reduced renal function, age-appropriate surgical consideration or calcium at the current guidelines referral threshold. Refer suspected cancer-associated hypercalcaemia to oncology and acute medicine; early source diagnosis affects both calcium control and prognosis. Nephrology advice is important when kidney disease complicates fluids, bisphosphonate use, dialysis or PTH interpretation.
In India, endocrine surgery, PTH assays, urinary calcium studies, denosumab, dialysis and oncology services may be concentrated in larger centres. Referral should name a reachable facility and should not delay emergency rehydration, ECG and transfer. Explain cost and access uncertainty honestly; no web guide can guarantee a particular infusion, scan or surgery. Pregnancy, frailty, heart failure, severe renal impairment and unstable malignancy deserve consultant-led decisions. A coordinated referral note should include corrected calcium trend, albumin, PTH, creatinine, ECG, symptoms, medications, fluids given and suspected cause.
Red Flags
Confusion, drowsiness, coma, seizures, acute psychosis, severe weakness, syncope, palpitations, shortened QT with dysrhythmia, hypotension, severe dehydration, oliguria and acute kidney injury are hypercalcaemic emergency features. Calcium above 3.5 mmol/L is an urgent correction threshold in Society for Endocrinology guidance because of dysrhythmia and coma risk. A patient with substantial symptoms at a lower calcium concentration, particularly after a rapid rise, still needs emergency review.
Cancer red flags include new severe bone pain, pathological fracture, spinal pain with weakness or sphincter symptoms, weight loss, anaemia, recurrent infection or unexplained renal decline. Hypercalcaemia can accompany myeloma, lymphoma and solid tumours; cord compression, sepsis and tumour lysis alternatives must not be missed. Do not delay urgent imaging or oncology contact while waiting for a PTH result if the patient is unstable.
Treatment red flags include fluid overload during rehydration, new breathlessness, falling urine output, worsening creatinine, hypocalcaemic symptoms after antiresorptive treatment, jaw symptoms or dental infection before planned potent antiresorptive therapy, and drug reactions. Pregnancy-related hypercalcaemia and neonatal risk require specialist endocrine-obstetric input. A reliable safety-net identifies the hospital, emergency transport and the reason to return; it should never advise a confused or vomiting patient to self-manage with extra water or over-the-counter calcium remedies.
Indian Clinical Context
The cited endocrine and oncology guidance is international and does not set Indian drug licences, package inserts, funding or referral criteria. Confirm current CDSCO product information, hospital formularies and specialist protocols before selecting a bisphosphonate, denosumab, calcitonin, cinacalcet or dialysis pathway. PTH, vitamin D, albumin-adjusted calcium, ionised calcium, urinary calcium and malignancy tests may not all be immediately available. State what is known, repeat a questionable result and transfer a critically ill patient rather than delaying care for a complete outpatient panel.
India-facing assessment must include locally available calcium and vitamin-D products, supplements, antacids, traditional medicines, tuberculosis or granulomatous disease history, cancer access and chronic kidney disease. These are prompts for history and testing, not assumptions about cause. Out-of-pocket cost may prevent serial calcium tests, infusions, imaging or endocrine surgery; a realistic plan should identify a government or private referral route and the monitoring that can actually be performed.
Evidence limitations deserve explicit disclosure. The emergency thresholds and malignancy regimens cited arise from international guidance and must be adapted to local laboratory units, assay methods, comorbidity and service capacity. NMC training supports electrolyte assessment, rational medicines, emergency recognition and referral, but formal competency codes should be checked in the adopted local curriculum. This guide is a reviewed review-queue draft, not an Indian guideline or completed clinical review.
NMC Competency Mapping
Hypercalcaemia connects medicine, endocrinology, oncology, nephrology, pharmacology and emergency care. Learners should recognise calcium-related dehydration, neurocognitive change, renal injury and ECG risk; take a supplement and medication history; interpret concurrent calcium and PTH; and form a PTH-dependent versus PTH-independent differential. They should distinguish biochemical confirmation from localisation imaging: neck imaging helps surgical planning after biochemical diagnosis, not diagnosis of primary hyperparathyroidism by itself.
At Know and Know How level, students explain why albumin matters, why a non-suppressed PTH is inappropriate in hypercalcaemia, and why primary hyperparathyroidism and malignancy dominate the differential. At Show How level, they assess volume status and mental state, prepare an emergency referral, identify fluid-overload risk, counsel about medicines and document a calcium trend. Antiresorptive, calcimimetic and dialysis prescribing are supervised tasks because renal function, vitamin D status and cause change their risk.
A suitable assessment uses a patient with constipation, stones and calcium 2.9 mmol/L, then asks for confirmation, PTH interpretation, urine calcium testing and referral. A second case with calcium 3.7 mmol/L, delirium and known cancer tests resuscitation, ECG, safe rehydration, antiresorptive principles and escalation. Professionalism includes avoiding blame about supplements or cancer, explaining uncertainty, respecting affordability and communicating return precautions to family. Consult the current NMC curriculum for code-level mapping.
Key Exam Pearls for NEET PG
The two dominant causes of hypercalcaemia are primary hyperparathyroidism and malignancy. Confirm albumin-adjusted calcium and interpret PTH concurrently. High calcium with inappropriately normal or high PTH points to primary or tertiary hyperparathyroidism; low PTH redirects to malignancy, vitamin D-related disease, granulomatous disease, medicines and other non-PTH causes. Familial hypocalciuric hypercalcaemia is usually mild and differentiated from primary hyperparathyroidism by urine calcium assessment.
Clinical features include polyuria, thirst, constipation, nausea, weakness, mood or cognitive change, renal impairment, shortened QT and dysrhythmia. Society for Endocrinology guidance classifies below 3.0 mmol/L as often non-urgent, 3.0-3.5 as potentially symptomatic and above 3.5 as requiring urgent correction. Severity also depends on rapidity and symptoms. Start with monitored rehydration; do not use loop diuretics routinely to lower calcium.
For severe hypercalcaemia of malignancy above 14 mg/dL or 3.5 mmol/L, Endocrine Society guidance supports calcitonin plus intravenous bisphosphonate or denosumab initially, limiting calcitonin to 48-72 hours. Bisphosphonates require renal caution and delayed calcium response. Glucocorticoids are for calcitriol-mediated causes, not all cases. Definitive primary hyperparathyroidism care is surgical assessment; do not confuse localisation imaging with biochemical diagnosis.
Frequently Asked Questions
Can one raised calcium result diagnose primary hyperparathyroidism?
No. Confirm the abnormality and interpret albumin-adjusted calcium with a concurrent PTH and the clinical context. Current guidelines recommends repeat albumin-adjusted calcium before PTH testing at specified thresholds. Dehydration, albumin or protein abnormalities and laboratory issues can mislead. A suppressed PTH shifts attention to malignancy and other non-parathyroid causes, while an inappropriately non-suppressed PTH requires endocrine assessment.
Should a patient with hypercalcaemia drink large volumes of water at home?
Not as a substitute for assessment. Mild stable cases may be advised to avoid dehydration by their clinician, but vomiting, confusion, kidney injury, heart failure, frailty or severe hypercalcaemia can make self-management unsafe. Emergency treatment uses monitored intravenous rehydration tailored to volume status. Excess unsupervised fluid can worsen heart failure or delay urgent care.
Are bisphosphonates safe for every hypercalcaemia cause?
No. They are used particularly for hypercalcaemia of malignancy after assessment, but kidney function, vitamin D status, cause, pregnancy, dental risk and previous therapy change the choice. They have a delayed effect and can cause renal deterioration or hypocalcaemia. Primary hyperparathyroidism may need surgery or selected calcimimetic therapy instead. Specialist guidance is needed for the individual regimen.
Does a normal PTH rule out primary hyperparathyroidism?
Not necessarily. In hypercalcaemia, PTH should physiologically be suppressed. A value within a laboratory reference range can still be inappropriately high and support primary hyperparathyroidism when interpreted with concurrent calcium. Current guidelines advises specialist discussion at defined PTH and calcium patterns. The result must also be distinguished from familial hypocalciuric hypercalcaemia and lithium-related disease.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic